Achieve Life Sciences is part of the healthcare sector and trades as part of the biotechnology industry. The company CEO is Richard Alistair Balfour Stewart. Achieve Life Sciences Inc is a United States based clinical-stage biopharmaceutical company. It is focused on the development of novel next generation cancer therapeutics.
Previous Intraday Performance:
The ACHV shares had a previous change of 6.34% which opened at 3.65 and closed at 3.86. It moved to an intraday high of 3.95 and a low of 3.65.
SeekingAlpha: Achieve Life Sciences, Inc. (ACHV) CEO Rick Stewart on Q1 2019 Results – Earnings Call Transcript
Historical Performance:
Over the last five trading days, ACHV shares returned 13.53% and in the past 30 trading days it returned 9.97%. Over three months, it changed 144.30%. In one year it has changed -67.29% and within that year its 52 week high was 10.50 and its 52 week low was 1.04. ACHV stock is 269.41% above its 52 week low.
Our calculations result in a 200 day moving average of 2.53 and a 50 day moving average of 3.67. Right now, ACHV stock is trading 52.63% above its 200 day moving average.
SeekingAlpha: Achieve Life Sciences, Inc. (ACHV) CEO Rick Stewart on Q1 2019 Results – Earnings Call Transcript
Liquidity:
The company has a market cap of $26.5m with 6.9m shares outstanding and a float of 4.3m shares. Trading volume was 161,089 shares and has experienced an average volume of 206,848 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for Achieve Life Sciences was -4.87 which ended on 31st of December 2018.
Below was the last reported quarterly diluted earnings per share:
| 1st | Qtr 2019 | -0.88 |
|---|---|---|
| 4th | Qtr 2018 | -0.55 |
| 3rd | Qtr 2018 | -0.71 |
| 2nd | Qtr 2018 | -1.82 |
| 1st | Qtr 2018 | -2.43 |
The growth of the EPS is critical in understanding the current valuation of Achieve Life Sciences.
Indicators Also to Watch:
Based on the latest filings, there is 28.10% of institutional ownership.
The beta was calculated to be 2.88.
SeekingAlpha: Achillion’s ACH-4471 shows encouraging action in PNH study; shares ahead 7% premarket
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -197.28%, return on assets is -140.22% and price-to-book is 2.60.
Company Score Card:
Results are out of six:
3 : Growth Expectations Result
3 : Financial Safety Result
0 : Past Performance Result
1 : Valuation Result
0 : Dividend Safety Result
1 : Overall Result
Related Tags: Achieve Life Sciences, ACHV, Biotechnology, Healthcare
